Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT C CARTWRIGHT

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1326129230
CMS profile
15135
Location
COLUMBUS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$22,635.67

88 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT C CARTWRIGHT

NPI 1326129230 · CMS profile ID 15135

Allopathic & Osteopathic Physicians / Allergy & Immunology

COLUMBUS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326129230?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT C CARTWRIGHT, NPI 1326129230, CMS profile ID 15135. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326129230?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERT C CARTWRIGHT, NPI 1326129230, CMS profile ID 15135. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326129230?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERT C CARTWRIGHT, NPI 1326129230, CMS profile ID 15135, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1326129230?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

88 matching records · $22,635.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 88 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–88 of 88.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BioCryst US Sales Co., LLC $19.7304/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012580791 CMS
Regeneron Healthcare Solutions, Inc. $22.1304/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999114291 CMS
AbbVie Inc. $13.0404/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996368195 CMS
CSL Behring $15.7104/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042910239 CMS
GlaxoSmithKline, LLC. $1,950.0004/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002153909 CMS
GlaxoSmithKline, LLC. $3,900.0004/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155873 CMS
PFIZER INC. $19.4204/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050557005 CMS
AbbVie Inc. $28.0503/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996368193 CMS
GlaxoSmithKline, LLC. $144.1003/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002153793 CMS
BioCryst US Sales Co., LLC $18.3703/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012580747 CMS
Regeneron Healthcare Solutions, Inc. $27.8703/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999114289 CMS
GlaxoSmithKline, LLC. $101.3403/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155753 CMS
GlaxoSmithKline, LLC. $15.9203/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155843 CMS
GlaxoSmithKline, LLC. $3,900.0003/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002153921 CMS
kaleo, Inc. $25.8603/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013059627 CMS
GlaxoSmithKline, LLC. $4.5403/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002153957 CMS
Regeneron Healthcare Solutions, Inc. $21.6703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999114285 CMS
AstraZeneca Pharmaceuticals LP $18.6903/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015932097 CMS
GlaxoSmithKline, LLC. $18.6602/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155831 CMS
BioCryst US Sales Co., LLC $28.9802/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012580699 CMS
GlaxoSmithKline, LLC. $3.6302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155789 CMS
GENZYME CORPORATION $30.0302/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049956855 CMS
CSL Behring $18.9002/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042910206 CMS
AstraZeneca Pharmaceuticals LP $14.6502/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016217479 CMS
GlaxoSmithKline, LLC. $4.8402/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002153945 CMS
Regeneron Healthcare Solutions, Inc. $24.9002/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999114279 CMS
GlaxoSmithKline, LLC. $1,300.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155707 CMS
Genentech USA, Inc. $22.0401/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040525141 CMS
PFIZER INC. $15.2701/25/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050630019 CMS
BioCryst US Sales Co., LLC $25.3501/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012580657 CMS
Regeneron Healthcare Solutions, Inc. $30.3901/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999114275 CMS
Teva Pharmaceuticals USA, Inc. $17.1601/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056775733 CMS
AstraZeneca Pharmaceuticals LP $15.1001/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015791183 CMS
Genentech USA, Inc. $30.1201/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040525125 CMS
GlaxoSmithKline, LLC. $21.1101/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002153897 CMS
AstraZeneca Pharmaceuticals LP $18.0801/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011902331 CMS
AstraZeneca Pharmaceuticals LP $51.2001/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015435637 CMS
GlaxoSmithKline, LLC. $9.4101/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002155821 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,345.08 66
PY2020 $14,274.40 59
PY2021 $55,803.98 106
PY2022 $59,056.25 130
PY2023 $22,635.67 88
PY2024 $7,357.29 81
PY2025 $2,546.23 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $154,792.92 22
PY2024 Principal investigator $19,564.07 6
PY2023 Principal investigator $5,997.51 3
PY2022 Principal investigator $40,720.13 31
PY2021 Principal investigator $91,098.70 81
PY2020 Principal investigator $81,742.59 44
PY2019 Principal investigator $114,902.79 73

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $3,466.00 12/22/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136521
Principal investigator 1 SANOFI US SERVICES INC. $4,555.00 12/15/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136509
Principal investigator 1 SANOFI US SERVICES INC. $293.44 12/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136506
Principal investigator 1 SANOFI US SERVICES INC. $288.79 11/24/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136501
Principal investigator 1 SANOFI US SERVICES INC. $656.38 11/10/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136447
Principal investigator 1 SANOFI US SERVICES INC. $3,602.00 11/10/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136451
Principal investigator 1 SANOFI US SERVICES INC. $8,515.00 11/10/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136455
Principal investigator 1 SANOFI US SERVICES INC. $8,829.00 11/10/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136470
Principal investigator 1 SANOFI US SERVICES INC. $15,000.00 10/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136420
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 10/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136425
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,742.11 10/10/2025 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185543576
Principal investigator 1 AstraZeneca UK Limited $299.00 10/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185543572
Principal investigator 1 SANOFI US SERVICES INC. $4,301.00 10/06/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136414
Principal investigator 1 SANOFI US SERVICES INC. $14,749.00 08/25/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136361
Principal investigator 1 SANOFI US SERVICES INC. $6,648.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136306
Principal investigator 1 SANOFI US SERVICES INC. $13,168.00 07/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136315
Principal investigator 1 SANOFI US SERVICES INC. $9,888.00 05/05/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136220
Principal investigator 1 AstraZeneca UK Limited $35,208.20 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185543570
Principal investigator 1 SANOFI US SERVICES INC. $130.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136143
Principal investigator 1 SANOFI US SERVICES INC. $35.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226136147
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,924.00 01/15/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185543568
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,995.00 01/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185543574